Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
Crossref DOI link: https://doi.org/10.1007/s13555-016-0139-0
Published Online: 2016-08-30
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kircik, Leon
Fowler, Joseph
Weiss, Jonathan
Meng, Xiangyi
Guana, Adriana
Nyirady, Judit
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation